References of "Wallemacq, Caroline"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailImpact thérapeutique du dépistage de l’ischémie myocardique silencieuse chez le sujet diabétique de type 2
Wallemacq, Caroline ULg; Scheen, André ULg

in Revue Médicale Suisse (2008), 168(4), 1800-1804

Coronary artery disease is the major cause of mortality of type 2 diabetic subjects. Its early diagnosis to prevent progression and clinical events has intuitive appeal. Somehow, rationale for screening ... [more ▼]

Coronary artery disease is the major cause of mortality of type 2 diabetic subjects. Its early diagnosis to prevent progression and clinical events has intuitive appeal. Somehow, rationale for screening has not been clearly established. Screening should not modify the medical therapy because diabetic subjects have to be treated in a secondary prevention strategy. We have no data from randomized trials concerning a better outcome after revascularization in this specific population. The question how to select the high risk population to be screened has no response by now. SPECT and stress echocardiography seem valuable for screening but not for risk stratification. A large randomized clinical trial is required to confirm the cost-utility ratio of such a screening. [less ▲]

Detailed reference viewed: 122 (4 ULg)
Full Text
Peer Reviewed
See detailLe cout du diabete de type 2: resume de l'enquete europeenne CODE-2 et analyse de la situation en Belgique.
Wallemacq, Caroline ULg; Van Gaal, L. F.; Scheen, André ULg

in Revue Médicale de Liège (2005), 60(5-6), 278-84

Type 2 diabetes mellitus is a common chronic disease whose economic impact on both patients and society is constantly increasing. "The Cost of Diabetes in Europe--Type 2 study" is the first coordinated ... [more ▼]

Type 2 diabetes mellitus is a common chronic disease whose economic impact on both patients and society is constantly increasing. "The Cost of Diabetes in Europe--Type 2 study" is the first coordinated attempt to measure total healthcare costs of type 2 diabetes mellitus in Europe. On average, 3% of the population with type 2 diabetes accounted for 5% of the total healthcare expenditure. Complications have a substantial impact on the costs of managing type 2 diabetes. The prevention of complications, especially cardiovascular disease, will potentially reduce overall healthcare expenditure. [less ▲]

Detailed reference viewed: 500 (2 ULg)